STOCK TITAN

Precipio Regains Listing Compliance with NASDAQ Minimum Bid Requirement

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Precipio, Inc. (NASDAQ: PRPO) has regained compliance with Nasdaq listing requirements, as confirmed by a letter received on June 29, 2020. The letter noted that the company's shares had maintained a closing bid price at or above $1.00 for ten consecutive business days. CEO Ilan Danieli expressed optimism about future growth opportunities, emphasizing a focus on enhancing shareholder value. Precipio aims to improve diagnostic accuracy through collaborations with leading academic institutions like Yale and Dana-Farber Cancer Institute, supporting patient care worldwide.

Positive
  • Regained compliance with Nasdaq listing requirements.
  • Shares maintained a closing bid price of above $1.00 for ten consecutive days.
Negative
  • None.

NEW HAVEN, Conn., July 01, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has regained compliance with the Nasdaq listing requirements. On June 29, 2020, the Company received a letter from Nasdaq stating that because the Company’s shares had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive business days, the Company’s stock had regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq, and that the matter is now closed. 

“With this matter behind us, the company can continue to focus on building strong shareholder value. We are excited about the many growth opportunities the company is working on, and we look forward to sharing those with our investors in the coming months,” said Ilan Danieli, Precipio’s CEO. 

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company’s Securities and Exchange Commission filings.

The company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

 

FAQ

What recent announcement did Precipio, Inc. make regarding its Nasdaq compliance?

Precipio announced it has regained compliance with Nasdaq listing requirements after maintaining a closing bid price above $1.00 per share for ten consecutive business days.

What is the stock symbol for Precipio, Inc.?

The stock symbol for Precipio, Inc. is PRPO.

When did Precipio receive confirmation of its Nasdaq compliance?

Precipio received confirmation of its Nasdaq compliance on June 29, 2020.

Who is the CEO of Precipio, Inc. and what did he say about future growth?

Ilan Danieli is the CEO of Precipio, who expressed excitement about future growth opportunities and enhancing shareholder value.

Precipio, Inc.

NASDAQ:PRPO

PRPO Rankings

PRPO Latest News

PRPO Stock Data

9.26M
1.48M
12.99%
8.79%
0.33%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
OMAHA